{"entity":{"id":"nct05704244","kind":"trial","name":"Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)","aka":[],"tldr":"A phase 3 trial of FE 999326 in bladder & urothelial cancer, run by Ferring Pharmaceuticals, active and no longer recruiting.","summary":"Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC) is a phase 3 interventional study registered as NCT05704244 by Ferring Pharmaceuticals, with 25 participants enrolled, started 2022-12-21 and due to reach its primary completion in 2029-11-30. Interventions recorded: FE 999326.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05704244","url":"https://clinicaltrials.gov/study/NCT05704244"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["ferring"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05704244","phase":"3","setting":"A Phase 3, Open Label Trial to Evaluate the Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)","sponsor":"Ferring Pharmaceuticals","enrolled":25,"outcomes":[]},"route":"/trials/nct05704244/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"company":[{"id":"ferring","kind":"company","name":"Ferring Pharmaceuticals","route":"/companies/ferring/"}]}}